Helio Genomics Partners with Quest Diagnostics to Boost Accessibility of Liver Cancer Detection Test

Collaboration to Enhance Early Liver Cancer Detection

In an innovative step forward for healthcare, Helio Genomics, a tech bio company harnessing AI for early cancer detection, has formed a partnership with Quest Diagnostics. This agreement aims to enhance the accessibility of HelioLiver™, a blood-based test designed for the early detection of Hepatocellular Carcinoma (HCC). Effective from April, healthcare providers linked with Quest Diagnostics will be able to order this test, thereby making it more accessible to patients across the U.S.

HelioLiver™ Test: A Groundbreaking Tool

The HelioLiver™ test distinguishes itself by relying on a simple blood sample, making it a less invasive alternative to traditional methods. It integrates sophisticated algorithms that analyze cell-free DNA methylation patterns alongside protein biomarkers and patient demographics. This advanced technique promises not only improved detection rates but also the potential to identify liver cancer in its early stages—prior to when ultrasound may provide conclusive results, a critical advantage for high-risk individuals.

Dr. Bharat Tewarie, CEO of Helio Genomics, emphasized that this partnership aligns perfectly with their mission to democratize cancer detection. By leveraging Quest's expansive infrastructure, they're set to enhance physician access to vital tools that can initiate treatment sooner, ultimately benefiting patient outcomes significantly.

Addressing a Rising Health Concern

Liver cancer has been progressively escalating as a public health threat in the United States, frequently going unnoticed until it reaches advanced stages due to a lack of early indicators. The alarming statistic of mortality related to liver cancer has tripled since 1980. However, when detected early, the five-year survival rate jumps to an impressive 70%. With an estimated 80-90% of at-risk adults bypassing ultrasounds due to various barriers, HelioLiver™ serves as a vital solution, promoting easier detection when curative options are most effective.

Quest's considerable resources—including roughly 7,700 patient service centers—will facilitate more straightforward access to the HelioLiver™ test, ensuring that healthcare providers can efficiently integrate testing into their existing protocols, including direct access through electronic health records.

A Future of Enhanced Healthcare

Critical gaps in current testing methods are addressed by the HelioLiver™ test, surpassing ultrasound efficacy in early-stage detection for high-risk patients, a revelation supported by multicenter studies. This technological advancement will not only aid in the early identification of liver cancers but will also ensure that millions of Americans have an additional avenue for early screening.

Both Helio Genomics and Quest Diagnostics are fostering a future where advanced cancer detection becomes routinely available. Given both parties' commitment, this collaboration is primed to make significant contributions to early cancer diagnosis and patient-centered care. As Helio Genomics proceeds with its laboratory testing in West Lafayette, Indiana, the immediate rollout of HelioLiver™ demonstrates a real dedication to confronting a burgeoning health crisis—liver cancer—head-on.

This partnership marks a significant milestone in the realm of oncology, poised to transform not just the landscape of liver cancer detection, but potentially set new industry standards for patient care moving forward.

For further details, healthcare providers are encouraged to visit Helio Genomics' official website for insights into the HelioLiver™ test and additional cancer detection solutions available through Quest Diagnostics.